Drugs / rHSA-GCSF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03251768 | Oct 2017 → Jul 2018 | neutropenia | Tianjin SinoBiotech Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rHSA-GCSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03251768 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein” NCT03251768 ↗ |
| Route | Subcutaneous | “will be injected subcutaneously at at 10 am (±90 min) on the 3th and 7th day of each chemotherapy cycle” NCT03251768 ↗ |